Important human respiratory viruses that cause respiratory infections (such as coronavirus, influenza virus, adenovirus, and respiratory syncytial virus) pose serious threats to public health. The ongoing COVID-19 pandemic caused by SARS-CoV-2 has led to more than 276 million confirmed cases and over 5.3 million deaths. It has also been estimated that the annual epidemic of influenza causes 290,000 to 650,000 deaths globally by WHO. Vaccines and antiviral agents are the two most effective measures to fight against viruses. However, the development of antiviral agents and vaccines is facing enormous challenges due to the constant variation of respiratory viruses and the prevalence of emerging and re-emerging viruses.
In the face of this grim situation, it is urgent to explore new methods of designing and developing more antiviral drugs/vaccines. We need to identify the activity of agents and vaccines at both laboratory and clinical levels, using molecular biology, structural biology, bioinformatics, and other methods to discover new targets of agents, and clarify the antiviral mechanism of highly effective agents and vaccines. These cutting-edge studies will provide important information for the fight against important human respiratory viruses.
In general, this Research Topic aims to advance the knowledge of the antiviral agents and vaccines against important human respiratory viruses. We welcome submissions dealing with the following themes, including but not limited to:
• Establishment of novel methods for the design and development of highly effective antiviral agents and vaccines.
• Screening and identifying the novel antiviral activity of old drugs; identifying new immunogenic epitopes; identification and mechanism exploration of new antiviral agents (such as antibody and small molecule drugs).
• Design and develop new antiviral vaccines, including but not limited to the nucleic acid vaccine, recombinant protein vaccine, polypeptide vaccine, and whole virus vaccine.
• Discovery and development of new therapeutic targets against important human respiratory viruses.
Important human respiratory viruses that cause respiratory infections (such as coronavirus, influenza virus, adenovirus, and respiratory syncytial virus) pose serious threats to public health. The ongoing COVID-19 pandemic caused by SARS-CoV-2 has led to more than 276 million confirmed cases and over 5.3 million deaths. It has also been estimated that the annual epidemic of influenza causes 290,000 to 650,000 deaths globally by WHO. Vaccines and antiviral agents are the two most effective measures to fight against viruses. However, the development of antiviral agents and vaccines is facing enormous challenges due to the constant variation of respiratory viruses and the prevalence of emerging and re-emerging viruses.
In the face of this grim situation, it is urgent to explore new methods of designing and developing more antiviral drugs/vaccines. We need to identify the activity of agents and vaccines at both laboratory and clinical levels, using molecular biology, structural biology, bioinformatics, and other methods to discover new targets of agents, and clarify the antiviral mechanism of highly effective agents and vaccines. These cutting-edge studies will provide important information for the fight against important human respiratory viruses.
In general, this Research Topic aims to advance the knowledge of the antiviral agents and vaccines against important human respiratory viruses. We welcome submissions dealing with the following themes, including but not limited to:
• Establishment of novel methods for the design and development of highly effective antiviral agents and vaccines.
• Screening and identifying the novel antiviral activity of old drugs; identifying new immunogenic epitopes; identification and mechanism exploration of new antiviral agents (such as antibody and small molecule drugs).
• Design and develop new antiviral vaccines, including but not limited to the nucleic acid vaccine, recombinant protein vaccine, polypeptide vaccine, and whole virus vaccine.
• Discovery and development of new therapeutic targets against important human respiratory viruses.
